Robert L. Strausberg

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Table 6 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers

  2023-04-03

• Supplementary Table 7 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers

  2023-04-03

• Supplemental figure legends from Altered Expression and Splicing of <i>ESRP1</i> in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic ActivityPreprint

  2023-04-03

• Supplementary Table 7 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers

  2023-04-03

• Supplementary Figure Legend from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for CancersPreprint

  2023-04-03

• Supplementary Table 1 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers

  2023-04-03

• Supplemental figure S1A, S1B, S2A, S2B, S3 from Altered Expression and Splicing of <i>ESRP1</i> in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic ActivityPreprint

  2023-04-03

• Supplemental table 1 from Altered Expression and Splicing of <i>ESRP1</i> in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic ActivityPreprint

  2023-04-03

• Supplementary Figure 2 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for CancersPreprint

  2023-04-03

• Supplementary Table 3 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers

  2023-04-03

• Supplementary Table 3 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers

  2023-04-03

• Supplementary Figure 1 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for CancersPreprint

  2023-04-03

• Supplementary Table 1 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers

  2023-04-03

• Supplementary Figure 2 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for CancersPreprint

  2023-04-03

• Supplemental figure legends from Altered Expression and Splicing of <i>ESRP1</i> in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic ActivityPreprint

  2023-04-03

• Supplemental table 1 from Altered Expression and Splicing of <i>ESRP1</i> in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic ActivityPreprint

  2023-04-03

• Data from Altered Expression and Splicing of <i>ESRP1</i> in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic ActivityPreprint

  2023-04-03

• Data from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for CancersPreprint

  2023-04-03

• Supplemental figure S1A, S1B, S2A, S2B, S3 from Altered Expression and Splicing of <i>ESRP1</i> in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic ActivityPreprint

  2023-04-03

• Supplementary Figure Legend from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for CancersPreprint

  2023-04-03